Randomized Controlled Trials

Ongoing CHRS Member Lead Multicenter Clinical Research Studies

NCT Number 

Title 

Other Names

Status

Study Results

Characteristics

NCT04428944

Title Acronym: STARAF3

Not yet recruiting

No Results Available

Study Type: Interventional

NCT04189822

Title Acronym:
HiRO

Enrolling by invitation

No Results Available

Study Type:
Observational

NCT03682991

Title Acronym:
RASTA AF

Recruiting

No Results Available

Study Type:
Interventional

NCT03636230

Title Acronym:
RPM CIED Brady

Recruiting

No Results Available

Study Type:
Interventional

NCT03593759

Title Acronym:
CHASM-CS-RCT

Recruiting

No Results Available

Study Type:
Interventional

NCT03405740

Title Acronym:
RPM CIED Tachy

Recruiting

No Results Available

Study Type:
Interventional

NCT03347227

Title Acronym:
COAST-AF RCT

Recruiting

No Results Available

Study Type:
Interventional

NCT02830360

Title Acronym:
VANISH2

Recruiting

No Results Available

Study Type:
Interventional

NCT02168829

Title Acronym:
OCEAN

Recruiting

No Results Available

Study Type:
Interventional

NCT01994252

Title Acronym:
RAFT-PermAF

Recruiting

No Results Available

Study Type:
Interventional

NCT01477359

Title Acronym:
CHASM-CS

Recruiting

No Results Available

Study Type:
Observational

NCT00673842

Title Acronym:
REFINE-ICD

Recruiting

No Results Available

Study Type:
Interventional

NCT05963698

Title Acronym:
LAAOS-4

Recruiting

No Results Available

Study Type:
Interventional

NCT06174220

Title Acronym:
TaRGET

Not yet recruiting 

No Results Available

Study Type:
Interventional

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

List of CHRS Members Lead Very High Impact Publications 
 

  1. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet. 1997;349(9053):675-682.  
     
  2. Gollob MH, Green MS, Tang AS, et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med. 2001;344(24):1823-1831. 
     
  3. Connolly SJ, Sheldon R, Thorpe KE, et al. Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope: Second Vasovagal Pacemaker Study (VPS II): a randomized trial. JAMA. 2003;289(17):2224-2229.
     
  4. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351(24):2481-2488. 
     
  5. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295(2):165-171. 
     
  6. Gollob MH, Jones DL, Krahn AD, et al. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N Engl J Med. 2006;354(25):2677-2688. 
     
  7. Gould PA, Krahn AD, Canadian Heart Rhythm Society Working Group on Device A. Complications associated with implantable cardioverter-defibrillator replacement in response to device advisories. JAMA. 2006;295(16):1907-1911. 
     
  8. Investigators AWGotA, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903-1912.
     
  9. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
     
  10. Investigators A, Connolly SJ, Pogue J, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360(20):2066-2078. 
     
  11. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L, Randomized Evaluation of Long-Term Anticoagulation Therapy I. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363(19):1875-1876. 
     
  12. Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363(25):2385-2395. 
     
  13. Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365(24):2268-2276.
     
  14. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-817.
     
  15. Investigators AI, Yusuf S, Healey JS, et al. Irbesartan in patients with atrial fibrillation. N Engl J Med. 2011;364(10):928-938. 
     
  16. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366(2):120-129. 
     
  17. Birnie DH, Healey JS, Wells GA, et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med. 2013;368(22):2084-2093. 
     
  18. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013; 369(13):1206-1214. 
     
  19. Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA. 2014;311(7):692-700. 
     
  20. Healey JS, Hohnloser SH, Glikson M, et al. Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE). Lancet. 2015;385(9970):785-791. 
     
  21. Morillo CA, Marin-Neto JA, Avezum A, et al. Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med. 2015;373(14):1295-1306. 
     
  22. Verma A, Jiang CY, Betts TR, et al. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med. 2015;372(19):1812-1822. 
     
  23. Healey JS, Oldgren J, Ezekowitz M, et al. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. Lancet. 2016;388(10050):1161-1169. 
     
  24. Sapp JL, Wells GA, Parkash R, et al. Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. N Engl J Med. 2016;375(2):111-121. 
     
  25. Connolly SJ, Eikelboom JW, Bosch J, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):205-218. 
     
  26. Andrade JG, Wells GA, Deyell MW, et al. Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. N Engl J Med. 2021;384(4):305-315.